Psoriatic Disease

For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no increased safety risks, according to data published in Arthritis Research & Therapy.

As the year comes to a close, Healio Dermatology has assembled this year’s top psoriasis articles. 

Earlier this year, the National Psoriasis Foundation published an extensive report on the health impacts of psoriasis, including data on social stigma associated with the disease, health disparities and comorbidities.

WASHINGTON — Dactylitis, psoriasis and other non-musculoskeletal manifestations of psoriatic arthritis can be accurately monitored through patient self-reporting, according to data presented at ACR Convergence 2024.

Deucravacitinib is superior to placebo for improving response across all domains of minimal disease activity criteria in patients with psoriatic arthritis at 16 weeks, according to data published in Rheumatology.

Ethan Craig, MD, spoke with Healio about diagnostic challenges in psoriatic arthritis.

The FDA has approved 320 mg pre-filled syringes and autoinjectors of Bimzelx for the treatment of active psoriatic arthritis with coexisting moderate-to-severe plaque psoriasis, according to a press release from UCB.

Treatment with apremilast led to improved clinical and patient-reported outcomes in early oligoarticular psoriatic arthritis at 16 weeks, according to data published in Annals of the Rheumatic Diseases.

SAN DIEGO — Certain dual therapy strategies, including interleukin-17 plus IL-23 inhibition, or Janus kinase inhibitors alongside TNF inhibitors, can be effective for difficult-to-treat inflammatory diseases, according to a speaker here.

SAN DIEGO — GLP-1 agonists and other drugs that have recently made headlines for their weight loss applications will be useful in helping patients meet goals in psoriatic arthritis and other rheumatic diseases, according to a speaker here.